Infus Nurs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Infus nurs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Infus Nurs Today - Breaking & Trending Today

First-of-its-Kind Randomized Clinical Trial Published in "The Lancet Infectious Diseases" Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters


Share this article
Share this article
FRANKLIN LAKES, N.J., Feb. 2, 2021 /PRNewswire/  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring peripheral intravenous catheters (PIVCs).
The results of the CLEAN3 trial
The Lancet Infectious Diseases, showed the use of the BD vascular care solution resulted in fewer PIVC failures compared with the standard group (34.8% vs. 47.5%, respectively) and extended the median time between catheter insertion and failure (50.4 hours vs 30.0 hours, respectively). PIVC failure was defined as any premature removal of PIVC before end of treatment – other than for routine replacement – and included phlebitis, infiltration, occlusion, dislodgment, local infection and catheter-related bloodstream infection (whichever occurred first). ....

Poitou Charentes , Franche Comter , Insyte Autoguard , Klaus Hoerauf , Troy Kirkpatrick , Kristenm Stewart , Medication Delivery Solutions , Poitiers University Hospital , Appl Health Econ , Lancet Infectious Diseases , Becton Dickinson , Infect Dis , Infus Nurs , Health Econ Policy , கிளாஸ் ொேறோஉப் , டிராய் கர்க்‌ப்யாட்ரிக் , மருந்து டெலிவரி தீர்வுகள் , அப்பில் ஆரோக்கியம் ஏகொன் , பெக்டன் டிக்கின்சன் , தொற்று திஸ் , ஆரோக்கியம் ஏகொன் பாலிஸீ ,

First-of-its-Kind Randomized Clinical Trial Published in The Lancet Infectious Diseases Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters


(2)
- There is robust evidence that the BD vascular care solution and skin antiseptic for peripheral intravenous catheters used in the CLEAN3 randomized clinical trial can help improve patient outcomes
- Compared with standard approaches, the BD vascular care solution reduced the relative risk of catheter failure by 27%, resulting in longer catheter dwell time without complications
- The use of 2% CHG 70% IPA single use, sterile applicator skin antiseptic reduced the risk of infectious complications (catheter colonization and local infection) by 92% compared with 5% povidone iodine (PVI) 69% ethanol
FRANKLIN LAKES, N.J., Feb. 2, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring peripheral intravenous catheters (PIVCs). ....

Poitou Charentes , Franche Comter , Kostenloser Wertpapierhandel , Insyte Autoguard , Olivier Mimoz , Klaus Hoerauf , Troy Kirkpatrick , Kristenm Stewart , Medication Delivery Solutions , Poitiers University Hospital , Appl Health Econ , Lancet Infectious Diseases , Professor Olivier Mimoz , Becton Dickinson , Infect Dis , Infus Nurs , Health Econ Policy , கிளாஸ் ொேறோஉப் , டிராய் கர்க்‌ப்யாட்ரிக் , மருந்து டெலிவரி தீர்வுகள் , அப்பில் ஆரோக்கியம் ஏகொன் , பெக்டன் டிக்கின்சன் , தொற்று திஸ் , ஆரோக்கியம் ஏகொன் பாலிஸீ ,